PR- and ER-positive were more common in the HER2-zero and HER2-low groups, whereas the HER2-positive group had a larger tumor size, higher Ki-67 index, and a higher proportion of lymph node metastases and calcifications in the training and test cohorts. The gene discussed is MKI67; the disease is neoplasm.